Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity (Q36648368)

15 August 2017

title

Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity (English)

1 reference

15 August 2017

1 reference

Arts EJ

1

1 reference

15 August 2017

Quiñones-Mateu ME

series ordinal

2

1 reference

15 August 2017

Albright JL

series ordinal

3

1 reference

15 August 2017

language of work or name

1 reference

1 March 1998

1 reference

15 August 2017

published in

Drug Resistance Updates

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

21-28

1 reference

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Current problems and the future of antiretroviral drug trials

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Anti-Retroviral and Pharmacological Properties of 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA)

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

The bottleneck in AZT activation

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Mechanism of DNA Strand Transfer Reactions Catalyzed by HIV-1 Reverse Transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980211-2

7 January 2021

10.1016/S1368-7646(98)80211-2

Identifiers

DOI

1 reference

15 August 2017

1 reference